ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1588

“Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA”

Ana Urruticoechea-Arana1, Iñigo Rúa-Figueroa2, Maria Auxiliadora Martin3, Fernando Sánchez-Alonso4, Francisco Javier López Longo5, María Galindo6, Alejandro Olivé7, Jaime Calvo-Alen8, Antonio Fernandez-Nebro9 and JM Pego-Reigosa10, 1Rheumatology, Hospital de Can Mises, Ibiza, Spain, 2Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, 3Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 4Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 5Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, 6Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 7Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 8Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, 9Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, 10Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Lupus and cancer

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

There is limited evidence on the risk of neoplasia in autoimmune diseases such as systemic lupus erythematosus. The objective of this study is to analyze the incidence of cancer in the Spanish population with SLE and the factors associated in its development: RelesSER Registry Data.

Methods:

We calculated the incidence density of malignant neoplasms, the standardized incidence ratio and the average time to develop the first neoplasm after diagnosis of SLE in patients of the SLE registry of the Spanish Rheumatology Society (RelesSER) fulfilling ACR97 criteria. We carried out a bivariate analysis of the associated factors to neoplasms and multivariate by logistic regression.

Results:

A total of 3607 patients (90.4% female) were included. We registered 140 neoplasms in women (4.3%) and 14 in men (4%) (p<0.821). Incidence density 7.3 / 1000 patient-years (95%CI:4.85-10.98) (7.39 in patient-years women and 6.93 in men) without significant differences. After stratification by gender and age, cancer appeared in 3.2% of the women aged under 45 versus 3.8% of the men; 4.1 % of women aged 45-65 years versus 5.9% of men and a 5.3% of women 65 and older versus 2.5% of men the same age. The standardized incidence ratio (SIR) was 2.16; 1.51 in men and 2.38 in women, highest for women under 65 years old. The SIR for > 65 years was 0.98; 0.59 in men and 1.55 in women.

The average time until de development of the first malignant neoplasm was 10 years (RI:5.75-17.00), being lower in women [9.5(RI:5.00-17.0) years] than in men [ 12.5(8.75-17.5)] and in patients under 45 years versus over 45 years [8.0(RI:5.00-16.00)].

Malignant neoplasms were the cause of death in 10% of the patients (15/154), predominantly hematological and breast cancers, both at 19% followed by lung cancer in 14.3%.

Factors associated to malignant neoplasms in the bivariate analysis are shown in (table 1). No immunosuppressive therapy was associated with the development of neoplasms. In the multivariate model, adjusted for age and time of disease duration, age was the only significant variable (OR:1.030; 95%CI: 1.003-1.059; p=0.029) with a trend for ACE inhibitors use (OR:1.866; 95%CI: 0.808-4.306; p= 0.144), SLEDAI (last visit) (OR :0.904; 95%CI: 0.806-1.015; p= 0.089, SLICC/ACR DI) (without neoplasias) (OR: 1.160; 95%CI: 0.961- 1.401; p= 0.123), and duration of the disease in months (OR: 1.003; 95% CI: 1.000–1.006; p= 0.068).

Conclusion:

The incidence of neoplasia in Spanish women with SLE is higher than expected for age and gender. Malignant neoplasms were the cause of death in 10 % of the patients, predominating hematological and breast cancers followed by lung cancer.

Acknowledgements:”The RelesSER registry has been supported by the FIS (ISCIII) – European Regional Development Fund (FEDER), fellowship PI11 / 02857.” It has also been partially funded by: GSK, UCB, Roche and Novartis.”

Table1- Factors associated to malignant neoplasms in the bivariate analysis

Cáncer

Control

Value of p

Gender, men %

4

96

0.821

Gender, women %

4.3

95.7

0.821

Age at last evaluation, years, mean (DS)

57.74 (14.38)

46.17 (14.58)

<0.001

SLICC*, median [p25-p75]

1.00 [0.00-3.00]

0.00 [0.00-1.00]

<0.001

CHARLSON*, median [p25-p75]

3 [2.00-4.00]

1 [1.00-3.00]

<0.001


Disclosure: A. Urruticoechea-Arana, None; I. Rúa-Figueroa, None; M. A. Martin, None; F. Sánchez-Alonso, None; F. J. López Longo, None; M. Galindo, None; A. Olivé, None; J. Calvo-Alen, None; A. Fernandez-Nebro, None; J. Pego-Reigosa, None.

To cite this abstract in AMA style:

Urruticoechea-Arana A, Rúa-Figueroa I, Martin MA, Sánchez-Alonso F, López Longo FJ, Galindo M, Olivé A, Calvo-Alen J, Fernandez-Nebro A, Pego-Reigosa J. “Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA” [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/neoplasia-in-patients-with-systemic-lupus-erythematosus-in-spain-relesser-registry-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neoplasia-in-patients-with-systemic-lupus-erythematosus-in-spain-relesser-registry-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology